Evidence map›Paper›PMID 29854319›Full record

ReviewOncotarget2018

Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review.

Maria Lopez-Santillan, Ane Larrabeiti-Etxebarria, Javier Arzuaga-Mendez, Elixabet Lopez-Lopez, Africa Garcia-Orad

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Expression and diagnostic significance of plasma exosomal RNA in diffuse large B-cell lymphoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Effects of hsa-miR-28-5p on Adriamycin Sensitivity in Diffuse Large B-Cell Lymphoma.Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maria Lopez-SantillanDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursery, University of The Basque Country (UPV/EHU), Leioa, Spain.
Ane Larrabeiti-EtxebarriaDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursery, University of The Basque Country (UPV/EHU), Leioa, Spain.
Javier Arzuaga-MendezDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursery, University of The Basque Country (UPV/EHU), Leioa, Spain.
Elixabet Lopez-LopezDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursery, University of The Basque Country (UPV/EHU), Leioa, Spain.
Africa Garcia-OradDepartment of Genetics, Physical Anthropology and Animal Physiology, Faculty of Medicine and Nursery, University of The Basque Country (UPV/EHU), Leioa, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and heterogeneous malignancy, with highly variable outcomes among patients. Although classification and prognostic tools have been developed, standard therapy still fails in 30-40% of patients. Hence, identification of novel biomarkers is needed. Recently, circulating microRNAs (miRNAs) have been suggested as non-invasive biomarkers in cancer. Our aim was to review the potential role of circulating miRNAs as biomarkers for diagnosis, classification, prognosis, and treatment response in DLBCL. We performed a search in PubMed using the terms [(('Non-coding RNA') OR ('microRNA' OR 'miRNA' OR 'miR') OR ('exosome') OR ('extracellular vesicle') OR ('secretome')) AND ('Diffuse large B cell lymphoma' OR 'DLBCL')] to identify articles that evaluated the impact of circulating miRNAs as diagnosis, subtype, treatment response or prognosis biomarkers in DLBCL in human population. Among the twelve articles that met the inclusion criteria, eleven considered circulating miRNAs as biomarkers for diagnosis, two for classification, and five for prognosis or treatment response. The limited number of studies performed and lack of consistency in results make it difficult to draw conclusions about the role of circulating miRNAs as non-invasive biomarkers in DLBCL. Although the preliminary associations observed seem promising, the only consistent result is the upregulation of mir-21 in DLBCL patients, which could be a biomarker for diagnosis. Further studies are needed.

Indexed as

circulating microRNAclassificationdiagnosislymphomaprognosis

Identifiers

PMID29854319
PMCPMC5978269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.